TNDM, US8753722037

Mizuho cuts target from USD 20 to USD 18 for Tandem Diabetes Care stock

Published on 10/15/2026 at 13:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 sales reached USD 254.56 million, up 5.77 percent year over year. Tandem Diabetes Care stock was EUR 14.25 on October 15, 2026.

Analyst target and sales growth

Mizuho cut its Tandem Diabetes Care target from USD 20 to USD 18 on October 13, 2026.
Second-quarter sales reached USD 254.56 million, up 5.77 percent year over year.
Tandem Diabetes Care stock was trading at EUR 14.25 at 1:05 p.m. CEST at Lang & Schwarz on October 15, 2026.

TNDM, US8753722037, Illustration mit AI erstellt.

Tandem Diabetes Care (ISIN US8753722037) was trading at EUR 14.25 at Lang & Schwarz on October 15, 2026 at 1:05 p.m. CEST. Mizuho analyst Anthony Petrone cut the price target from USD 20 to USD 18 on October 13, 2026, while keeping a Neutral rating, according to Markets Insider.

Three milestones shape TNDM

Business Wire reported that Tandem's second-quarter results on August 6, 2026 included USD 254.56 million in sales and a 57 percent gross margin. The company announced on September 28, 2026 that its Tandem Mobi automated insulin delivery system had become available in 12 international markets. On October 1, 2026, it set November 5, 2026 for its third-quarter results.

What drives the next test?

The second-quarter sales figure was 5.77 percent above the year-earlier level, but the company still reported a net loss of USD 21.17 million for the quarter ended June 30, 2026. The loss translated into diluted GAAP earnings per share of minus USD 0.31, according to the standardized quarterly financial statement data for Tandem Diabetes Care. Mizuho's lower USD 18 target reflects a more cautious near-term view ahead of the third-quarter update. The cited report said the firm expected procedure-volume headwinds linked to Affordable Care Act and Medicaid contraction.

November 5 results set the date

The next reporting date is November 5, 2026, after the market close. Business Wire said Tandem will discuss the results during a conference call at 4:30 p.m. ET. That update will test whether the international expansion and pharmacy-channel strategy can support the company's 2026 sales outlook of USD 1.065 billion to USD 1.085 billion.

Price remains the live reference

The euro quote places Tandem Diabetes Care at EUR 14.25 at Lang & Schwarz on October 15, 2026 at 1:05 p.m. CEST. The primary listing is Nasdaq, where the stock was last quoted at USD 16.01 on October 14, 2026 at 4:00 p.m. ET. Tandem's market capitalization was USD 1.1 billion as of October 14, 2026, with a 52-week range of USD 12.26 to USD 29.65.

The further course of trading is shown by the continuously updated real-time quote of Tandem Diabetes Care stock.